Navigation Links
Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
Date:11/17/2010

on as a tablet or liquid; and no evidence to date of renal toxicity.  Uniquely among potential smallpox therapeutics, CMX001's safety and efficacy may be evaluated in patients with life-threatening dsDNA virus infections which share many basic traits with variola virus.  Further, CMX001 may be effective in the treatment of and protection against smallpox among the estimated 80-90 million Americans whose immune systems are compromised, such as those under treatment for cancer and many chronic diseases or people living with HIV.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 300 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  In Chimerix's ongoing placebo-controlled studies, CMX001 has been administered to more than 200 patients and healthy volunteers.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 120 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment.  To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. CMX001 is also being developed as a medical countermeasure in the event of a smallp
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
2. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
3. Chimerix to Present at Upcoming Investor Conferences
4. Chimerix Initiates Phase 1 Study of CMX157
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
7. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
8. Chimerix Joins International Network of Organizations to Cure Malaria
9. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
10. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 According to a ... Growth, Trends & Forecasts (2015-2020), , published by Mordor Intelligence, ... billion by the end of 2020, with North ... more than 40% of the global market size. The Global ... CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Neuropathology services for VA and Military health systems 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... England, April 21 Vantia Therapeutics, a,company developing ... today announces the appointment of Rachel Morten as ... Rachel has more than 24 years experience in ... and animal health industries. Most,recently an independent regulatory ...
... Scientists at the Cambridge University have discovered that freshwater ... around each other, miraculously held together only by the ... published today in the journal Physical Review Letters ... which consists of approximately 1,000 cells arranged on the ...
... University of Illinois have found a new way to ... self-aligned, and defect-free nanowire channels made of gallium arsenide. ... (Institute of Electrical and Electronics Engineers) journal Electron ... engineering professor Xiuling Li and graduate research assistant Seth ...
Cached Biology Technology:Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 2Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 3Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 4Scientists discover 'dancing' algae 2Self-assembled nanowires could make chips smaller and faster 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... owners love their children, they tend to share more of ... cohorts rather than their kids. That is just ... of Colorado Boulder that looked at the types and transfer ... (or paws) of members of 60 American families, including canines. ...
... tissue-specific cells can be grown in abundance from mature ... according to scientists at the University of Pittsburgh School ... Their experiments, reported today in Scientific Reports , ... of cells or agents to artificially support cell growth ...
... is pleased to announce it has received a grant ... Advanced Life Sciences Training Program. The grant will ... July 2013 for all five classes of participants in ... 2008. The Fellows Program is a high-level life science ...
Cached Biology News:CU-Boulder study looks at microbial differences between parents, kids and dogs 2CU-Boulder study looks at microbial differences between parents, kids and dogs 3CU-Boulder study looks at microbial differences between parents, kids and dogs 4Recipe for large numbers of stem cells requires only one ingredient, says NIH/Pitt team 2Keystone Symposia announces grant from Alfred P. Sloan Foundation 2
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... PureLink PCR Purification Kits provide rapid and ... short-failed PCR products, and salts from PCR ... procedure:, provides two Binding Buffer options ... , can be performed in either single ...
... capped transcripts with the translation boosting Cap ... 100% capped (versus 40% to 80% capped ... about 2 hours. mScript™ also features the ... to be up to 50% more efficient ...
Biology Products: